cefixime has been researched along with 7432 s in 26 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (3.85) | 18.7374 |
| 1990's | 16 (61.54) | 18.2507 |
| 2000's | 8 (30.77) | 29.6817 |
| 2010's | 1 (3.85) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Iseki, K; Miyazaki, K; Sugawara, M | 1 |
| Iseki, K; Kondo, Y; Miyazaki, K; Shiroto, H; Sugawara, M; Uchino, J | 1 |
| Doyle, WJ; Pinero, BP; Rosenfeld, RM; Seroky, J; Swarts, JD | 1 |
| Gudipati, S; Midkiff, BR; Westblom, TU | 1 |
| Barry, AL; Jones, RN | 1 |
| Hashimoto, A; Iseki, K; Kobayashi, M; Miyazaki, K; Sugawara, M | 1 |
| Hashimoto, A; Iseki, K; Kobayashi, M; Miyazaki, K; Sugawara, M; Takahashi, M; Toda, T | 1 |
| Rodriguez, WJ; Wiedermann, BL | 1 |
| Doyle, WJ; Greene, I; Rosenfeld, RM; Seroky, J; Swarts, JD | 1 |
| Kumano, K; Kuroyama, M; Motohashi, S; Murase, S; Tomonaga, F | 1 |
| Blandino, G; Nicoletti, G; Speciale, A | 1 |
| Itokazu, GS; Karavokiros, KT; Schatz, BS; Taeubel, MA | 1 |
| Verbist, L; Verhaegen, J | 1 |
| Arcidiacono, MM; Demartini, G; Dugnani, S; Fraschini, F; Pintucci, JP; Scaglione, F | 1 |
| Fung, CP; Ho, MW; Liu, CY; Wang, FD | 1 |
| Amores, R; Calvo, A; Prieto, J; Sevillano, D; Valero, E | 1 |
| Ganapathy, ME; Ganapathy, V; Leibach, FH; Mackenzie, B; Prasad, PD | 1 |
| Inui, K; Mukai, M; Saito, H; Terada, T | 2 |
| Brandsch, M; Luckner, P | 1 |
| Tsuji, A | 1 |
| Biegel, A; Brandsch, M; Gebauer, S; Hartrodt, B; Neubert, K; Thondorf, I | 1 |
| Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
| Ho, KM; Leung, AO; Lo, AC; Lo, JY; Tapsall, JW; Tiu, FS; Tsang, GK | 1 |
| González-Díaz, H; Orallo, F; Quezada, E; Santana, L; Uriarte, E; Viña, D; Yáñez, M | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
3 review(s) available for cefixime and 7432 s
| Article | Year |
|---|---|
The role of newer oral cephalosporins, fluoroquinolones, and macrolides in the treatment of pediatric infections.
Topics: Administration, Oral; Anti-Bacterial Agents; Anti-Infective Agents; Azithromycin; Bacterial Infections; Cefixime; Cefotaxime; Cefpodoxime Proxetil; Cefprozil; Ceftibuten; Ceftizoxime; Cefuroxime; Cephalosporins; Child; Clarithromycin; Fluoroquinolones; Humans | 1994 |
Comparison of cefprozil, cefpodoxime proxetil, loracarbef, cefixime, and ceftibuten.
Topics: Bacterial Infections; Cefixime; Cefotaxime; Cefpodoxime Proxetil; Cefprozil; Ceftibuten; Ceftizoxime; Cephalosporins; Humans; Microbial Sensitivity Tests; Prodrugs; Randomized Controlled Trials as Topic | 1996 |
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
2 trial(s) available for cefixime and 7432 s
| Article | Year |
|---|---|
Interpretation of middle ear fluid concentrations of antibiotics: comparison between ceftibuten, cefixime and azithromycin.
Topics: Acute Disease; Administration, Oral; Adolescent; Anti-Bacterial Agents; Azithromycin; Cefixime; Cefotaxime; Ceftibuten; Cephalosporins; Child; Exudates and Transudates; Female; Humans; Male; Otitis Media with Effusion; Time Factors | 1999 |
Comparative study of ceftibuten and cefixime in the treatment of complicated urinary tract infections.
Topics: Adult; Aged; Aged, 80 and over; Cefixime; Ceftibuten; Cephalosporins; Enterobacteriaceae; Enterobacteriaceae Infections; Female; Humans; Male; Middle Aged; Treatment Outcome; Urinary Tract Infections | 2001 |
21 other study(ies) available for cefixime and 7432 s
| Article | Year |
|---|---|
H+ coupled transport of orally active cephalosporins lacking an alpha-amino group across brush-border membrane vesicles from rat small intestine.
Topics: Animals; Cefixime; Cefotaxime; Ceftibuten; Cephalosporins; Hydrogen; In Vitro Techniques; Intestine, Small; Male; Membranes; Microvilli; Rats; Rats, Inbred Strains | 1991 |
Transport characteristics of ceftibuten, cefixime and cephalexin across human jejunal brush-border membrane.
Topics: Biological Transport, Active; Cefixime; Cefotaxime; Ceftibuten; Cephalexin; Cephalosporins; Glucose; Humans; Hydrogen; In Vitro Techniques; Jejunum; Microvilli | 1991 |
Third-generation cephalosporins in the treatment of acute pneumococcal otitis media. An animal study.
Topics: Acoustic Impedance Tests; Acute Disease; Ampicillin; Animals; Cefixime; Cefotaxime; Ceftibuten; Cephalosporins; Chinchilla; Drug Evaluation, Preclinical; Otitis Media with Effusion; Pneumococcal Infections | 1992 |
In vitro susceptibility of Helicobacter pylori to the new oral cephalosporins cefpodoxime, ceftibuten and cefixime.
Topics: Administration, Oral; Cefixime; Cefotaxime; Cefpodoxime; Ceftibuten; Ceftizoxime; Cephalosporins; Drug Resistance, Microbial; Enterobacteriaceae; Helicobacter pylori; Microbial Sensitivity Tests | 1990 |
In vitro evaluation of ceftibuten (7432-S, SCH 39720), a novel orally administered cephalosporin.
Topics: Administration, Oral; Cefaclor; Cefixime; Cefotaxime; Ceftibuten; Cefuroxime; Cephalexin; Cephalosporins; Enterobacteriaceae; Haemophilus influenzae; Microbial Sensitivity Tests; Moraxella catarrhalis; Neisseria meningitidis; Streptococcus | 1988 |
Effect of membrane surface potential on the uptake of anionic compounds by liposomes.
Topics: Anions; Cefixime; Cefotaxime; Ceftibuten; Cell Membrane Permeability; Cephalosporins; Hydroxyindoleacetic Acid; Liposomes; Membrane Potentials; Phosphatidylserines | 1994 |
Changes in the permeation rate of organic anions through the intestinal brush-border membrane with membrane surface potential.
Topics: Anilino Naphthalenesulfonates; Animals; Anions; Cefixime; Cefotaxime; Ceftibuten; Cephalosporins; Diffusion; Fluorescent Dyes; Hydrogen-Ion Concentration; Intestinal Mucosa; Membrane Potentials; Microvilli; Penicillin G; Permeability; Rats | 1994 |
Efficacy of ceftibuten for acute otitis media caused by Hemophilus influenzae: an animal study.
Topics: Acute Disease; Ampicillin; Animals; Anti-Bacterial Agents; Cefixime; Cefotaxime; Ceftibuten; Cephalosporins; Chinchilla; Haemophilus Infections; Haemophilus influenzae; Otitis Media; Random Allocation | 1993 |
[Protein binding of oral cephems in patients with chronic renal failure].
Topics: Carrier Proteins; Cefdinir; Cefixime; Cefotaxime; Ceftibuten; Cephalosporins; Humans; Kidney Failure, Chronic; Palmitic Acid; Palmitic Acids; Renal Dialysis | 1993 |
Third generation oral cephalosporins: comparative in vitro kinetics.
Topics: Administration, Oral; Cefixime; Cefotaxime; Ceftibuten; Ceftizoxime; Cephalosporins; Escherichia coli; Haemophilus influenzae; Kinetics; Klebsiella pneumoniae; Microbial Sensitivity Tests; Moraxella catarrhalis; Streptococcus pneumoniae; Streptococcus pyogenes | 1995 |
In-vitro activity of 21 beta-lactam antibiotics against penicillin-susceptible and penicillin-resistant Streptococcus pneumoniae.
Topics: Amoxicillin; Ampicillin; Anti-Bacterial Agents; beta-Lactams; Carbapenems; Cefaclor; Cefadroxil; Cefatrizine; Cefepime; Cefixime; Cefotaxime; Cefpirome; Cefpodoxime; Ceftazidime; Ceftibuten; Ceftizoxime; Ceftriaxone; Cefuroxime; Cephalosporins; Cephradine; Drug Resistance, Microbial; Drug Resistance, Multiple; Humans; Microbial Sensitivity Tests; Penicillin Resistance; Penicillins; Piperacillin; Pneumococcal Infections; Serotyping; Species Specificity; Streptococcus pneumoniae | 1998 |
[Activity of different antimicrobial agents against penicillin-resistant Streptococcus pneumoniae].
Topics: Amoxicillin; Anti-Bacterial Agents; Azithromycin; Cefaclor; Cefixime; Cefpodoxime; Ceftibuten; Ceftizoxime; Cefuroxime; Cephalosporins; Clavulanic Acid; Community-Acquired Infections; Drug Resistance, Multiple, Bacterial; Humans; Microbial Sensitivity Tests; Penicillin Resistance; Pneumonia, Pneumococcal; Spain; Streptococcus pneumoniae | 2001 |
Interaction of anionic cephalosporins with the intestinal and renal peptide transporters PEPT 1 and PEPT 2.
Topics: Animals; Biological Transport; Caco-2 Cells; Carrier Proteins; Cell Line; Cephalosporins; Colon; Dipeptides; Evoked Potentials; HeLa Cells; Humans; Kidney; Microvilli; Oocytes; Peptide Transporter 1; Rats; Rats, Inbred SHR; Rats, Sprague-Dawley; Symporters; Transfection; Xenopus laevis | 1997 |
Characterization of stably transfected kidney epithelial cell line expressing rat H+/peptide cotransporter PEPT1: localization of PEPT1 and transport of beta-lactam antibiotics.
Topics: Animals; Anti-Bacterial Agents; beta-Lactams; Biological Transport; Cell Line; Dose-Response Relationship, Drug; Epithelium; Hydrogen; Kidney; Peptides; Rats; Transfection | 1997 |
Recognition of beta-lactam antibiotics by rat peptide transporters, PEPT1 and PEPT2, in LLC-PK1 cells.
Topics: Animals; Anti-Bacterial Agents; Biological Transport; Carrier Proteins; Ceftibuten; Cephalosporins; Cyclacillin; Dipeptides; Hydrogen-Ion Concentration; Kidney; Kinetics; LLC-PK1 Cells; Peptide Transporter 1; Rats; Recombinant Proteins; Structure-Activity Relationship; Symporters; Transfection | 1997 |
Interaction of 31 beta-lactam antibiotics with the H+/peptide symporter PEPT2: analysis of affinity constants and comparison with PEPT1.
Topics: Animals; Anti-Bacterial Agents; beta-Lactams; Binding Sites; Caco-2 Cells; Dose-Response Relationship, Drug; Humans; Peptide Transporter 1; Protein Binding; Rats; Symporters | 2005 |
Transporter-mediated Drug Interactions.
Topics: | 2002 |
Three-dimensional quantitative structure-activity relationship analyses of beta-lactam antibiotics and tripeptides as substrates of the mammalian H+/peptide cotransporter PEPT1.
Topics: Animals; beta-Lactams; Cell Line, Tumor; Dipeptides; Drug Design; Humans; Mammals; Models, Molecular; Oligopeptides; Peptide Transporter 1; Quantitative Structure-Activity Relationship; Substrate Specificity; Symporters | 2005 |
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Ceftibuten resistance and treatment failure of Neisseria gonorrhoeae infection.
Topics: Anti-Bacterial Agents; Ceftibuten; Cephalosporin Resistance; Cephalosporins; Female; Genes, Bacterial; Gonorrhea; Humans; Male; Microbial Sensitivity Tests; Neisseria gonorrhoeae; Treatment Failure | 2008 |
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.
Topics: Computational Biology; Drug Design; Humans; Isoenzymes; Molecular Structure; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Quantitative Structure-Activity Relationship | 2008 |